RxDoctor Payments Data

Usman Piracha, MD

Cardiovascular Disease · Chesapeake, VANPI 1245548841

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 65 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$234
  • Novartis$217
  • Cook Incorporated$141
  • Boehringer Ingelheim$132
  • Amgen$112
  • Pfizer$110
  • plus $484 from 9 others

What the payments were for

  • Grants$14110%
  • Food & beverage$1,28890%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,429 in reported general payments places this provider in the 45th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$272,101
Medicare patients
1,920
Services billed
4,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$161,636
EntrestoSacubitril/Valsartan58$64,126
JardianceEmpagliflozin44$31,264
XareltoRivaroxaban21$20,376
BrilintaTicagrelor16$8,419
Metoprolol Succinate232$3,360
Atorvastatin Calcium161$1,917
Ranolazine ErRanolazine14$1,529
Valsartan33$1,246
Spironolactone112$1,188
Ezetimibe53$1,155
Rosuvastatin Calcium75$879
Amlodipine Besylate161$847
Carvedilol68$737
Losartan Potassium107$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$161,636142 claims
NovartisEntresto$217$64,12658 claims
Boehringer IngelheimJardiance$132$31,26444 claims
Johnson & JohnsonXarelto$81$20,37621 claims
AstraZenecaBrilinta$59$8,41916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →